OTC · Medical - Devices

Antibe Therapeutics Inc. (ATBPF) Stock

$0.22 -0.19% OTC: ATBPF Healthcare

Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices.

Valuation

MetricValue
Price$0.22
Market Cap$11.43M
P/E Ratio-0.80
P/B Ratio0.38
P/S Ratio0.00
EPS (TTM)$-0.37
52-Week High$0.22
52-Week Low$0.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.16%
ROA-27.60%
ROCE-30.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio15.03

Annual Financials (USD)

Metric20192020202120222023
Revenue$10.0M$10.0M$10.0M$0$0
Operating Profit$-12.0M$-19.0M$-24.0M$-26.0M$-21.0M
Net Profit$-13.0M$-19.0M$-26.0M$-25.0M$-19.0M
EPS$-0.60$-0.71$-0.70$-0.49$-0.37
Op Margin-127.8%-192.6%-242.3%——

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$15.0M$14.0M$82.0M$89.0M$71.0M
Total Liabilities$7.0M$10.0M$31.0M$32.0M$30.0M
Cash$6.0M$6.0M$72.0M$35.0M$7.0M
Borrowings$2.0M$2.0M$0$0$0

Latest News

TowneBank Q2 Earnings, Revenue Rise MT Newswires · Jul 23, 2026 Renault says sales stalled in first half AFP · Jul 23, 2026 Should You Buy Amazon and Meta Platforms Stocks Before July 29? Motley Fool · Jul 23, 2026 argenx Q2 Profit, Total Operating Income Rise MT Newswires · Jul 23, 2026 STMicroelectronics Q2 Non-GAAP Earnings, Revenue Rise MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-7.0M$-12.0M$0$-17.0M$-16.0M
Investing Cash Flow$0$0$0$-20.0M$-12.0M
Financing Cash Flow$3.0M$4.0M$-1.0M$0$0
Net Cash Flow$2.0M$0$66.0M$-37.0M$-28.0M
Free Cash Flow$-7.0M$-12.0M$0$-17.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-0.46
FCF Yield-104.32%
Quick Ratio15.03
Interest Coverage-2568.25
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CDXFFCloud DX Inc. $0.09 +12.50% -1.14 $9.75M 0.00%
CNPOFRIV Capital Inc. $0.08 +0.00% -0.15 $10.96M 0.00%
EIGRQEiger BioPharmaceuticals, Inc. $8.50 +6.25% -0.17 $12.59M 0.00%
LVCLYLiving Cell Technologies Limited $0.03 +24.39% -11.54 $11.39M 0.00%
LXXGFLexaGene Holdings Inc. $0.08 +0.00% -0.89 $11.34M 0.00%

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.

Antibe Therapeutics Inc. is headquartered in CA.

Antibe Therapeutics Inc. (ATBPF) stock trades at $0.22 with a market capitalization of $11.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.80, price-to-book of 0.38, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.19 and $0.22, and currently trades at its 52-week high.

On profitability, Antibe Therapeutics Inc. generates a return on equity (ROE) of -40.16%, return on capital employed of -30.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.antibethera.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides